GEN-001

Generic Name
GEN-001
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

First Posted Date
2023-08-21
Last Posted Date
2024-03-21
Lead Sponsor
Genome & Company
Target Recruit Count
148
Registration Number
NCT05998447
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center., Seoul, Korea, Republic of

and more 3 locations

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

First Posted Date
2022-06-15
Last Posted Date
2023-10-17
Lead Sponsor
Genome & Company
Target Recruit Count
42
Registration Number
NCT05419362
Locations
🇰🇷

Ajou University Hospital, Gyeonggi-do, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

and more 2 locations

Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

Not Applicable
Conditions
Locally Advanced Rectal Cancer
Interventions
Drug: GEN-001
First Posted Date
2021-10-15
Last Posted Date
2021-10-15
Lead Sponsor
Korean Cancer Study Group
Target Recruit Count
40
Registration Number
NCT05079503

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

First Posted Date
2020-10-23
Last Posted Date
2023-08-08
Lead Sponsor
Genome & Company
Target Recruit Count
11
Registration Number
NCT04601402
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy